Short- and long-term effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women

Chang Gung Medical Journal

Volumn 24, Issue 7, 2001, Pages 431-439

  Chen, F P ^a   Lee, N ^a   Soong, Y K ^a   Huang, K E ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Hemostatic parameters; Hormone replacement therapy; Lipoprotein profile; Platelet aggregation

Indexed keywords

ANTITHROMBIN III; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; POSTMENOPAUSE; RISK FACTOR; SHORT COURSE THERAPY; THROMBOCYTE AGGREGATION;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HEMOSTASIS; HUMANS; LIPIDS; LIPOPROTEINS; MIDDLE AGED; PLATELET AGGREGATION; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 0034862081     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. A review of association of estrogens and progestins with cardiovascular disease in postmenopausal women
2. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
3. Hormones and cardiovascular disease: Oral contraceptives and hormone replacement therapy: Different effects on coronary heart disease, deep venous thrombosis and stroke
4. Cardiovascular effects of estrogen and lipid-lowing therapies in postmenopausal women
5. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkerys: Lack of an effect of added progesterone
6. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
7. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
8. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
9. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women
10. Changes in lipoprotein in postmenopausal women receiving hormone replacement therapy
11. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
12. Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy
13. The menopause and hormone replacement therapy: Lipids, lipoproteins, coagulation and fibrinolytic factors
14. Plasma fibrinogen in women: Relationship with oral contraception, the menopause and hormone replacement therapy
15. Haemostatic variables and menopausal status: Influence of hormone replacement therapy
16. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women
17. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: A placebo-controlled study with nomegestrol acetate and estradiol
18. Epidemiology of coagulation factors, inhibitors and activation markers: The third Glasgow MONICA survey. I. Illustrative reference ranges by age, sex and hormone use
19. High plasminogen activator inhibitor and tissue plasminogen acivator levels in plasma prec[l]ede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor
20. Predictive value of fibrinolytic factors in coronary heart disease
21. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring study
22. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status
23. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators
24. Estrogen replacement therapy and the risk of venous thrombosis
25. Risk and prophylaxis for venous thromboembolism in hospital patients
26. Risk of venous thromboembolism in users of hormone replacement therapy
27. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
28. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
29. Prospective study of exogenous hormones and risk of pulmonary embolism in women
30. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables
31. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial
32. Antithrombin III and arterial disease
33. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women
34. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions